Erasca (ERAS) Stock: Buy, Sell, or Hold?
ERAS - Erasca, Inc. Common Stock
$15.14
0.56 (3.84%)
▲
5d:
+6.25%
30d:
-7.51%
90d:
-19.68%
HOLD
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Oct 1, 2026 at $14.58 · last confirmed Oct 1, 2026
Strength: 4.8/10
Get Alerted When ERAS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ERAS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ERAS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ERAS is currently trading at $15.14, which is considered slightly low relative to its 30-day fair value range of $14.54 to $17.47.
Technical Outlook: Technically, ERAS is in a uptrend. Immediate support is located at $13.54, while resistance sits at $15.78. The stock is showing strong short-term momentum, up 3.8% recently.
Market Sentiment: ERAS scores 69/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $24.11 (+65.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ERAS is in a uptrend. Immediate support is located at $13.54, while resistance sits at $15.78. The stock is showing strong short-term momentum, up 3.8% recently.
Market Sentiment: ERAS scores 69/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $24.11 (+65.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$14.54 -
$17.47
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
100.0%
Protect Your Profits
Holding ERAS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (69/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.8%)
- BULLISH: Trading 65.4% below Wall St target ($24.11)
- CAUTION: Bottoming setup, but lagging the sector by 23% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$14.54 -
$17.47
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$13.54
Resistance Level
$15.78
Current Trend
Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-23.40
Wall Street Target
$24.11
(+65.4%)
Share & Embed Analysis
Last updated: October 02, 2026 9:58 AM ET
Data refreshes hourly during market hours. Next update: 10:58 AM
Data refreshes hourly during market hours. Next update: 10:58 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ERAS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 59 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 63 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 73 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 61 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 44 HOLD |
Advanced ERAS Option Strategies
Professional options setups generated by AI based on today's ERAS price and gamma walls.
